CALR mutations are infrequent in WHO-defined refractory anemia with ring sideroblasts

Leukemia

Volumn 28, Issue 6, 2014, Pages 1370-1371

  Patnaik, M M ^a   Belachew, A ^a   Finke, C ^a   Lasho, T L ^a   Hanson, C A ^a   Tefferi, A ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALRETICULIN; JANUS KINASE 2;

DISEASE CLASSIFICATION; GENE EXPRESSION; GENE MUTATION; HUMAN; LETTER; LEUKOCYTE COUNT; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; SOMATIC MUTATION; SPLICEOSOME; THROMBOCYTE COUNT; THROMBOCYTOSIS; WORLD HEALTH ORGANIZATION; BONE MARROW BIOPSY; CYTOGENETICS; EXON; GENE FREQUENCY; MYELOID METAPLASIA; THROMBOCYTHEMIA;

AGED; ANEMIA, REFRACTORY; ANEMIA, SIDEROBLASTIC; CALRETICULIN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MALE; MUTATION; PROGNOSIS; WORLD HEALTH ORGANIZATION;

EID: 84902082280     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2014.47     Document Type: Letter

References (11)

1. Klampfl T, Gisslinger H, Harutyunyan AS, Nivarthi H, Rumi E, Milosevic JD et al. Somatic mutations of calreticulin in myeloproliferative neoplasms. N Engl J Med 2013; 369: 2379-2390.
2. Nangalia J, Massie CE, Baxter EJ, Nice FL, Gundem G, Wedge DC et al. Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2. N Engl J Med 2013; 369: 2391-2405.
3. Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH et al. CALR vs JAK2 vs MPL mutated or triple-negative myelofibrosis: Clinical, cytogenetic and molecular comparisons. Leukemia 2014; e-pub ahead of print 9 January 2014, doi:10.1038/leu.2014.3.
4. Rotunno G, Mannarelli C, Guglielmelli P, Pacilli A, Pancrazzi A, Pieri L et al. Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. Blood 2013; e-pub ahead of print 26 December 2013.
5. Patnaik MM, Hanson CA, Sulai NH, Hodnefield JM, Knudson RA, Ketterling RP et al. Prognostic irrelevance of ring sideroblast percentage in World Health Organization-defined myelodysplastic syndromes without excess blasts. Blood 2012; 119: 5674-5677.
6. Patnaik MM, Lasho TL, Hodnefield JM, Knudson RA, Ketterling RP, Garcia-Manero G et al. SF3B1 mutations are prevalent in myelodysplastic syndromes with ring sideroblasts but do not hold independent prognostic value. Blood 2012; 119: 569-572.
7. Swederlow S, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al. WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC: Lyon, France, 2008.
8. Patnaik MM, Hanson CA, Hodnefield JM, Lasho TL, Finke CM, Knudson RA et al. Differential prognostic effect of IDH1 versus IDH2 mutations in myelodysplastic syndromes: A Mayo Clinic study of 277 patients. Leukemia 2012; 26: 101-105.
9. Patnaik MM, Lasho TL, Finke CM, Hanson CA, Hodnefield JM, Knudson RA et al. Spliceosome mutations involving SRSF2, SF3B1, and U2AF35 in chronic myelomonocytic leukemia: Prevalence, clinical correlates, and prognostic relevance. Am J Hematol 2013; 88: 201-206.
10. Schmitt-Graeff A, Thiele J, Zuk I, Kvasnicka HM. Essential thrombocythemia with ringed sideroblasts: A heterogeneous spectrum of diseases, but not a distinct entity. Haematologica 2002; 87: 392-399. (Pubitemid 34297546)
11. Lasho TL, Finke CM, Hanson CA, Jimma T, Knudson RA, Ketterling RP et al. SF3B1 mutations in primary myelofibrosis: Clinical, histopathology and genetic correlates among 155 patients. Leukemia 2012; 26: 1135-1137.